Same injections method, same dosing frequency
NUFYMCO is given as an injection to the eye and dosed in the same way as LUCENTIS®. Treatment is typically monthly, but your doctor will assess and recommend an appropriate dosing schedule for you.
Not actual patients
NUFYMCO is an FDA-approved prescription treatment for
these retinal conditions:
FDA-approved indications:
- wAMD Wet age-related macular degeneration
- RVO
Macular edema after
retinal vein occlusion - DME Diabetic macular edema
- DR Diabetic retinopathy
- mCNV Myopic choroidal neovascularization
About NUFYMCO
NUFYMCO is an FDA-approved biosimilar that is interchangeable with LUCENTIS®
NUFYMCO can be used in the same eye conditions as LUCENTIS®
This means it is expected to work in the same way, with the same safety and effectiveness as LUCENTIS®
As there are no clinically meaningful differences between NUFYMCO and LUCENTIS®, your provider can choose to start or transition you to NUFYMCO without affecting your treatment.
A biosimilar is a type of medicine that is proven to be clinically equivalent to an FDA-approved biologic, in this case, LUCENTIS®.
Biosimilars help reduce out of pocket costs for patients, making important treatments available for those who need them.
Biosimilars like Nufymco are carefully and rigorously evaluated through an FDA-approved process, and are required to meet high FDA standards for consistent manufacturing to ensure quality.
NUFYMCO is an FDA-approved biosimilar that is interchangeable with LUCENTIS®
NUFYMCO can be used in the same eye conditions as LUCENTIS®
A biosimilar is a type of medicine that is proven to be clinically equivalent to an FDA-approved biologic, in this case, LUCENTIS®.
This means it is expected to work in the same way, with the same safety and effectiveness as LUCENTIS®
Biosimilars help reduce out of pocket costs for patients, making important treatments available for those who need them.
As there are no clinically meaningful differences between NUFYMCO and LUCENTIS®, your provider can choose to start or transition you to NUFYMCO without affecting your treatment.
Biosimilars like Nufymco are carefully and rigorously evaluated through an FDA-approved process, and are required to meet high FDA standards for consistent manufacturing to ensure quality.
Not actual
healthcare providers
With NUFYMCO, you can expect the same treatment approach and similar treatment results as with LUCENTIS®
Backed by Zydus (USA), a leading US generics manufacturer
Quality of development and manufacturing through European and US partners
NUFYMCO is developed and manufactured in Europe through established biosimilar partners and brought to practices and their patients in the US by Zydus (USA).
Zydus (USA), a leading US generics manufacturer, is part of Zydus Lifesciences, a fully integrated, global healthcare provider with over 70 years’ experience.
The same effectiveness and safety
NUFYMCO may be substituted for LUCENTIS® or started instead of LUCENTIS® without compromising the treatment impact or safety.
Support throughout your treatment journey
ZySupport* is there to help eligible patients and healthcare professionals navigate coverage, access, and financial support for prescribed Zydus medicines.
*Terms and conditions apply.